The Manufacturers Life Insurance Company boosted its holdings in Spark Therapeutics, Inc. (NASDAQ:ONCE) by 19.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 18,259 shares of the biotechnology company’s stock after acquiring an additional 2,975 shares during the period. The Manufacturers Life Insurance Company owned 0.06% of Spark Therapeutics worth $1,091,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Spark Therapeutics by 11.6% during the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Spark Therapeutics by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock worth $114,968,000 after purchasing an additional 96,803 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Spark Therapeutics by 3.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,607,972 shares of the biotechnology company’s stock worth $96,060,000 after purchasing an additional 58,879 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Spark Therapeutics during the 2nd quarter worth about $30,848,000. Finally, Victory Capital Management Inc. boosted its stake in shares of Spark Therapeutics by 1.2% during the 2nd quarter. Victory Capital Management Inc. now owns 417,410 shares of the biotechnology company’s stock worth $24,936,000 after purchasing an additional 4,750 shares during the last quarter. 77.94% of the stock is currently owned by hedge funds and other institutional investors.

ONCE has been the topic of several analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a research note on Tuesday, October 10th. SunTrust Banks, Inc. set a $101.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 16th. Cowen and Company reaffirmed a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a research note on Tuesday, October 10th. Cantor Fitzgerald set a $94.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Royal Bank Of Canada decreased their price target on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $90.36.

Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) opened at $72.25 on Monday. Spark Therapeutics, Inc. has a 12-month low of $47.03 and a 12-month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The company had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. During the same period in the prior year, the business posted ($1.07) earnings per share. Spark Therapeutics’s revenue was up 45.8% on a year-over-year basis. equities research analysts anticipate that Spark Therapeutics, Inc. will post -7.62 earnings per share for the current fiscal year.

In related news, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $83.30, for a total value of $416,500.00. Following the transaction, the insider now owns 215,000 shares in the company, valued at $17,909,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Stephen W. Webster sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $79.38, for a total transaction of $793,800.00. Following the completion of the transaction, the chief financial officer now owns 12,500 shares in the company, valued at approximately $992,250. The disclosure for this sale can be found here. Insiders sold 1,080,850 shares of company stock worth $91,191,774 in the last 90 days. 7.30% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “The Manufacturers Life Insurance Company Raises Position in Spark Therapeutics, Inc. (ONCE)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/13/the-manufacturers-life-insurance-company-raises-position-in-spark-therapeutics-inc-once.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.